Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations

Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations

Resistance to chemotherapy, enhanced proliferation, invasion, angiogenesis, and metastasis (RPIAM) represent major obstacles that limit the efficacy of cancer treatment especially in advanced stages of cancer. Overcoming or suppressing RPIAM can dramatically improve the treatment outcome. Non-small...

Full description

Bibliographic Details
Main Authors:	Joydeb Majumder, Tamara Minko
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Pharmaceutics
Subjects:	EGFR mutated and gefitinib-resistant NSCLC lipid nanoparticles siRNA LHRH paclitaxel
Online Access:	https://www.mdpi.com/1999-4923/13/7/1063

Similar Items

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
by: Tingting Liao, et al.
Published: (2022-09-01)

Cabazitaxel-loaded human serum albumin nanoparticles combined with TGFβ-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer
by: Tiantian Tan, et al.
Published: (2023-07-01)

Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy
by: Chung-Yu Huang, et al.
Published: (2020-01-01)

The codelivery of siRNA and QDs by pH-responsive micelle for hepatoma cancer cells
by: Cao, Zhonglin, et al.
Published: (2020)

Brain-targeted polymersome codelivery of siRNA and temozolomide for effective glioblastoma chemo-RNAi synergistic therapy
by: Meng Zheng, et al.
Published: (2022-07-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel
Published: (2020-03-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
by: Stephen V. Liu, et al.
Published: (2023-09-01)

Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation
by: Xing-Xing Fan, et al.
Published: (2014-03-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

Engineering siRNA therapeutics: challenges and strategies
by: Syed Saqib Ali Zaidi, et al.
Published: (2023-10-01)

A Multifunctional Hybrid Nanocarrier for Non-Invasive siRNA Delivery to the Retina
by: Shogo Nishida, et al.
Published: (2023-02-01)

Construction of PEI‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
by: Guixue Yang, et al.
Published: (2022-11-01)

Multifunctional polymeric micelles for delivery of drugs and siRNA
by: Aditi M. Jhaveri, et al.
Published: (2014-04-01)

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs
by: Jun CHEN, et al.
Published: (2010-04-01)

Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells
by: Li Chen, et al.
Published: (2023-07-01)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
by: Antonio Rossi, et al.
Published: (2022-02-01)

SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth
by: Zenghua Sheng, et al.
Published: (2023-08-01)

Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity
by: Yan Mu, et al.
Published: (2022-07-01)

Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations
by: Miaomiao Li, et al.
Published: (2022-06-01)

Nanoparticles and siRNA: A new era in therapeutics?
by: María Dolores Pérez-Carrión, et al.
Published: (2024-03-01)

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
by: Di Hu, et al.
Published: (2023-06-01)

Implications of siRNA Therapy in Bone Health: Silencing Communicates
by: Puneetpal Singh, et al.
Published: (2024-01-01)

Structural Modifications of siRNA Improve Its Performance In Vivo
by: Ivan V. Chernikov, et al.
Published: (2023-01-01)

Uncommon <i>EGFR</i> Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
by: Ilaria Attili, et al.
Published: (2022-01-01)

Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles
by: Mahmoud S. Hanafy, et al.
Published: (2023-12-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01)

Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC
by: Carlos Pedraz-Valdunciel, PhD, et al.
Published: (2023-12-01)

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
by: Obradovic Jasmina, et al.
Published: (2012-12-01)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01)

NSCLC With Synchronous EGFR Mutations in Li Fraumeni Syndrome: A Case Report
by: Jennifer A. Marks, MD, et al.
Published: (2023-06-01)

Landscape and Predictive Significance of the Structural Classification of <i>EGFR</i> Mutations in Chinese NSCLCs: A Real-World Study
by: Linping Gu, et al.
Published: (2022-12-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

Tetrazine-Induced Bioorthogonal Activation of Vitamin E-Modified siRNA for Gene Silencing
by: Xueli Zhang, et al.
Published: (2022-07-01)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Jason S. Agulnik, et al.
Published: (2022-02-01)

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
by: Yen‐Ting Lin, et al.
Published: (2024-01-01)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
by: Shoko Sonobe Shimamura, et al.
Published: (2022-03-01)

Two Birds with One Stone: A Novel Dithiomaleimide-Based GalNAc-siRNA Conjugate Enabling Good siRNA Delivery and Traceability
by: Sudong Kong, et al.
Published: (2023-10-01)

A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review
by: Li D, et al.
Published: (2023-01-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)